At Uromigos Live 2024, a panel moderated by Brian Rini focused on the use of front-line therapy in papillary renal cancer and featured discussion on new and upcoming data in the field. The panel featured Tom Powles along with guests Laurence Albiges, MD, Institute Gustave-Roussy; David McDermott, MD, Beth Israel Deaconess Medical Center; and Hans Hammers, MD, UT Southwestern Medical Center.
In the second part of the session, the panel highlights some of the most important recent developments in treating papillary renal cell carcinoma.
Uromigos Live 2024 Front-Line Therapy in Papillary RCC Part 2: Major Data in Front-Line Papillary RCC
By Brian Rini, MD, FASCO, Thomas Powles, MBBS, MRCP, MD, Laurence Albiges, MD, PhD, David F. McDermott, MD, Hans Hammers, MD, PhD - Last Updated: October 30, 2024Related Posts
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.